Log In
BCIQ
Print this Print this
 

PRT-300

  Manage Alerts
Collapse Summary General Information
Company Prothelia Inc.
DescriptionSmall molecule
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentDiscovery
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD); Treat limb girdle muscular dystrophy 2I (LGMD2I); Treat merosin-deficient congenital muscular dystrophy type 1A (MDC1A)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today